FindTrial
Sign In

Double-way ultrasonography in evaluating benign and malignant salivary gland tumors

Double-way ultrasonography in evaluating benign and malignant salivary gland tumors

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065335
Enrollment
Unknown
Registered
2022-11-02
Start date
2022-11-02
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

salivary gland tumors

Interventions

Transvenous contrast-enhanced ultrasound group:Ultrasound contrast medium was injected intravenously
Transcatheter contrast-enhanced ultrasound group:Ultrasound contrast medium was injected into the catheter

Sponsors

Qilu Hospital of Shandong University (Qingdao), China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
10 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with salivary gland neoplasms diagnosed by ultrasonography.

Exclusion criteria

Exclusion criteria: 1. Contraindications of severe cardiopulmonary insufficiency; 2. Ultrasound contrast agent allergy.

Design outcomes

Primary

MeasureTime frame
The extent of the lesion after contrast-enhanced ultrasound;Mode and time of ultrasonic peak-reaching;—

Countries

China

Contacts

Public ContactLi Xiaoguang

Qilu Hospital of Shandong University (Qingdao)

qlyylxg@163.com+86 18561810938

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026